Mid-to-high teens revenue growth in FY27
Management expects revenue growth of mid-to-high teens, driven primarily by volume (75%) and mix (25%), with no price increases planned.
THYROCARETECHNOLOGIES / guidance tracker
Keep management guidance in view.
Thyrocare Technologies · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
Stable EBITDA margins around 32-34% in FY27
Normalized EBITDA margin expected to remain stable at ~34% as operating leverage is reinvested into growth initiatives.
Franchise additions of ~500 per quarter
Management targets adding approximately 500 net new franchises each quarter, consistent with current run rate.
Specialty mix to reach 15-20% in 3 years
Management aims to increase specialty testing (genomics, allergy) to 15-20% of revenue within three years, from a low base.